The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

Please provide your email address to receive an email when new articles are posted on . Topical medications are widely preferred by physicians and patients to treat psoriasis. Steroidal agents should ...

AJMC: Please describe the process for the treatment of psoriasis currently at your health system, Emory Healthcare. What guidelines/pathways are involved? HAUMSCHILD: Our psoriasis treatment approach ...

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint was ...

Subgroup analyses from one of the agent's pivotal trials showed that 29.5% of adolescents receiving icotrokinra achieved PASI ...

In a recent study published in the journal Frontiers in Immunology, researchers use a multi-omics approach combining immune cell-enriched single-cell transcriptomics (scRNA-seq), microarray analysis, ...

EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable ...